Kristoffer Danielsson
CEO Jarlen Capital
Kristoffer Danielsson is the Founder and CEO of Jarlen Capital, a boutique cross border biopharma BD consultancy. He specializes in early stage asset scouting and strategic partnering in oncology and immunology, focusing on targeted therapies such as ADCs, B/TrsAb, PROTACs, and radiopharmaceuticals. Kristoffer has facilitated high value deals with leading pharmaceutical companies including GSK, Daiichi Sankyo, AstraZeneca, J&J, and Takeda. He brings deep expertise in deal structuring, due diligence, and global BD strategy, providing insights into commercializing precision oncology innovations. Kristoffer is passionate about advancing next generation targeted radiopharmaceuticals through strategic industry partnerships that accelerate development and improve patient outcomes.
Seminars
- Identifying the scientific, clinical and commercial characteristics investors believe will differentiate tomorrow’s category leaders from an increasingly crowded pipeline
- Exploring which risks remain most significant to investment decisions, from manufacturing scalability and reimbursement to target differentiation and regulatory execution
- Evaluating the milestones that create the greatest enterprise value and discussing where capital should be deployed to maximise long-term commercial success
